Article Text

Download PDFPDF
Hot off the breath: triple therapy for idiopathic pulmonary fibrosis—hear the PANTHER roar
  1. Emmet E McGrath1,
  2. Ann B Millar2
  1. 1Centre for Translational Inflammation Research, School of Clinical and Experimental Medicine, University of Birmingham, Edgbaston, Birmingham, UK
  2. 2Lung Research Group, School of Clinical Sciences, University of Bristol Paul O'Gorman Lifeline Centre, Southmead Hospital, Westbury-on-Trym, UK
  1. Correspondence to Dr Emmet E McGrath, Centre for Translational Inflammation Research, School of Clinical and Experimental Medicine, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; e.e.mcgrath{at}bham.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Idiopathic pulmonary fibrosis (IPF) is a disease characterised by alveolar epithelial damage followed by an aberrant repair mechanism characterised by fibroblast foci and activated myofibroblasts.1 Despite an incidence of 7.4/100 000 person years which is increasing year on year and a median survival of only 2–3 years, there is paucity of evidence for effective therapy.2 The current British Thoracic Society guidelines weakly recommend N-acetylcysteine (NAC), prednisolone and azathioprine (based on the IFIGENIA—Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine I Annual—trial) whereas the more recent guidelines of the American Thoracic Society/European Respiratory Society recommend lung transplantation or participation in a clinical trial as treatment options.3–5

 Increasing recognition of the clinical need for effective IPF therapy has finally led to a number of clinical trials evaluating potential anti-inflammatory and anti-fibrotic agents. IFIGENIA demonstrated that triple therapy with NAC, azathioprine and prednisolone was better than azathioprine and prednisolone in combination in preserving lung function in IPF patients, suggesting that NAC inclusion was strongly contributing to the benefits …

View Full Text

Footnotes

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Airwaves
    Andrew Bush Ian Pavord